Zeo ScientifiX, Inc. (ZEOX)

Current Report Filed: 2026-04-21

ZEO has trained over 500 clinicians through its monthly Masterclass series in regenerative biologics treatments, demonstrating progress in building a professional practitioner network and expanding market reach in the regenerative medicine space.
The company is not listed on any major exchange (no securities registered under Section 12(b)), indicating it remains a micro-cap or OTC-traded entity with limited liquidity and institutional investor access.
This 8-K represents a non-material corporate event (Item 8.01) rather than a significant business development, suggesting the milestone announcement is primarily for awareness-building rather than disclosing financial impact or operational changes.

Current Report Filed: 2026-04-09

Zeo ScientifiX has entered into an exclusive strategic collaboration with Regen Therapy, positioning Zeo as the core supplier of advanced biologic therapeutics for Regen's regenerative offerings.
The collaboration with Regen Therapy could provide Zeo with a significant revenue stream and growth opportunity in the regenerative medicine market.
The agreement seems to align with Zeo's focus on developing and supplying innovative biologic solutions, which could be a key driver of the company's future success.

Current Report Filed: 2026-04-07

ZEO ScientifiX, Inc. has been selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition, which could provide the company with increased visibility, funding, and potential partnership opportunities.
The company's selection for the XPRIZE Healthspan competition indicates its products or technologies may have promising potential in the healthcare/longevity space, which could be a growth area for the company.
Investors may want to closely monitor the company's progress in the XPRIZE competition and any subsequent updates or developments that could impact the company's future prospects.

Current Report Filed: 2026-03-27

The company has terminated the employment of its Chief Science Officer, Dr. John D. Kisiday, Ph.D., effective March 23, 2026. This could signal changes in the company's scientific leadership and strategic direction.
The filing does not provide any details or explanation for the termination of the Chief Science Officer, which raises questions about the reasons behind this decision and its potential impact on the company's operations and future prospects.
As Zeo ScientifiX, Inc. is a Nevada-based company with the ticker symbol ZEOX, investors should closely monitor any further developments or updates regarding the leadership changes and their potential implications for the company's performance and growth trajectory.

Annual Report Filed: 2026-01-29

Zeo ScientifiX, Inc. (ZEOX) has experienced significant customer concentration risk, with 3 large customers accounting for a substantial portion of its sales revenue in both fiscal years 2024 and 2025.
The company has made significant investments in manufacturing equipment and finance lease equipment, indicating potential capacity expansion or upgrades to support future growth.
Zeo ScientifiX has a substantial amount of convertible debt and warrants outstanding, which could lead to future dilution for existing shareholders if exercised.

Current Report Filed: 2026-01-21

Zeo ScientifiX, Inc. granted restricted stock awards to its CEO, CFO, and Chief Medical Officer, aligning their incentives with shareholders.
The company plans to vest the stock awards over an 8-month and 1-year period, indicating a focus on long-term growth and retention.
As an OTC-listed company, Zeo ScientifiX does not trade on a major exchange, which may limit its visibility and access to capital markets.

Insider Trading Filed: 2026-01-16

The reporting person, George Craig Shapiro, was granted 175,000 restricted shares of the company's common stock under the 2021 Equity Incentive Plan. This suggests the company is providing additional equity-based compensation to its Chief Medical Officer, potentially to incentivize and retain him.
The restricted shares vest 50% after 8 months and the remaining 50% after 12 months, indicating a relatively short vesting period that could align the officer's interests with the company's short-term performance.
The reporting person now holds a total of 578,021 shares of the company's common stock, representing a significant ownership stake that could align his interests with those of other shareholders.

Insider Trading Filed: 2026-01-16

Ian T. Bothwell, the CEO and CFO of Zeo ScientifiX, Inc. (ZEOX), has acquired 175,000 shares of the company's common stock, increasing his beneficial ownership to 915,094 shares.
The shares were granted under the company's 2021 Equity Incentive Plan, with 50% vesting in 8 months and the remaining 50% vesting in 12 months, indicating management's long-term commitment to the company.
The insider acquisition suggests Bothwell's confidence in the company's future prospects and could signal a positive outlook for the stock.

Insider Trading Filed: 2026-01-16

Wendy Grey, a director and 10% owner of Zeo ScientifiX, Inc. (ZEOX), received a grant of 175,000 restricted shares under the company's 2021 Equity Incentive Plan, suggesting management's confidence in the company's future.
The vesting schedule of the restricted shares, with 50% vesting in 8 months and the remaining 50% in 12 months, indicates that the company is incentivizing long-term commitment from Ms. Grey.
The insider ownership structure, with Greyt Ventures, LLC (owned by a trust for which Ms. Grey is the trustee) holding a significant stake, aligns the interests of management and shareholders.

Important Information